Renaissance Technologies LLC increased its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 3.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,201,500 shares of the specialty pharmaceutical company’s stock after acquiring an additional 40,537 shares during the period. Renaissance Technologies LLC owned approximately 2.00% of Jazz Pharmaceuticals PLC worth $186,833,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Somerset Trust Co raised its stake in shares of Jazz Pharmaceuticals PLC by 0.4% in the second quarter. Somerset Trust Co now owns 3,194 shares of the specialty pharmaceutical company’s stock valued at $497,000 after acquiring an additional 14 shares in the last quarter. Level Four Advisory Services LLC raised its stake in shares of Jazz Pharmaceuticals PLC by 0.8% in the first quarter. Level Four Advisory Services LLC now owns 2,729 shares of the specialty pharmaceutical company’s stock valued at $389,000 after acquiring an additional 23 shares in the last quarter. World Asset Management Inc raised its stake in shares of Jazz Pharmaceuticals PLC by 1.9% in the second quarter. World Asset Management Inc now owns 1,441 shares of the specialty pharmaceutical company’s stock valued at $224,000 after acquiring an additional 27 shares in the last quarter. Profund Advisors LLC raised its stake in shares of Jazz Pharmaceuticals PLC by 1.3% in the second quarter. Profund Advisors LLC now owns 2,915 shares of the specialty pharmaceutical company’s stock valued at $453,000 after acquiring an additional 38 shares in the last quarter. Finally, Nomura Asset Management Co. Ltd. raised its stake in shares of Jazz Pharmaceuticals PLC by 0.8% in the first quarter. Nomura Asset Management Co. Ltd. now owns 6,550 shares of the specialty pharmaceutical company’s stock valued at $951,000 after acquiring an additional 50 shares in the last quarter. Institutional investors and hedge funds own 88.24% of the company’s stock.

JAZZ has been the topic of a number of analyst reports. Cantor Fitzgerald restated a “buy” rating and issued a $197.00 price target on shares of Jazz Pharmaceuticals PLC in a research note on Tuesday, June 27th. Royal Bank Of Canada set a $210.00 price target on Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a research note on Tuesday, June 27th. Mizuho cut Jazz Pharmaceuticals PLC from a “buy” rating to a “neutral” rating and cut their price target for the company from $162.00 to $150.00 in a research note on Tuesday, July 4th. Deutsche Bank AG restated a “buy” rating and issued a $176.00 price target on shares of Jazz Pharmaceuticals PLC in a research note on Tuesday, July 4th. Finally, Janney Montgomery Scott raised their price target on Jazz Pharmaceuticals PLC from $138.00 to $175.00 and gave the company a “buy” rating in a research note on Tuesday, July 4th. One analyst has rated the stock with a sell rating, three have given a hold rating and nineteen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $180.96.

In other Jazz Pharmaceuticals PLC news, Director Paul L. Berns sold 662 shares of the company’s stock in a transaction dated Friday, August 11th. The shares were sold at an average price of $142.37, for a total value of $94,248.94. Following the completion of the transaction, the director now owns 6,599 shares in the company, valued at approximately $939,499.63. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Suzanne Sawochka Hooper sold 4,580 shares of the company’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $160.00, for a total transaction of $732,800.00. Following the completion of the transaction, the executive vice president now owns 32,322 shares of the company’s stock, valued at approximately $5,171,520. The disclosure for this sale can be found here. In the last 90 days, insiders sold 8,297 shares of company stock valued at $1,279,417. 4.30% of the stock is owned by insiders.

WARNING: “Renaissance Technologies LLC Has $186.83 Million Stake in Jazz Pharmaceuticals PLC (JAZZ)” was posted by Daily Political and is the property of of Daily Political. If you are reading this report on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.dailypolitical.com/2017/09/24/renaissance-technologies-llc-has-186-83-million-stake-in-jazz-pharmaceuticals-plc-jazz.html.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) traded up 0.07% during trading on Friday, hitting $147.89. The company had a trading volume of 187,044 shares. Jazz Pharmaceuticals PLC has a 12 month low of $95.80 and a 12 month high of $163.75. The company has a market cap of $8.88 billion, a PE ratio of 22.78 and a beta of 1.13. The company’s 50 day moving average price is $148.82 and its 200-day moving average price is $150.52.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last posted its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 EPS for the quarter, missing the consensus estimate of $1.85 by ($0.13). Jazz Pharmaceuticals PLC had a return on equity of 22.75% and a net margin of 25.69%. The firm had revenue of $394.39 million during the quarter, compared to the consensus estimate of $410.83 million. During the same quarter last year, the company posted $2.67 EPS. Jazz Pharmaceuticals PLC’s revenue for the quarter was up 3.5% on a year-over-year basis. Equities analysts expect that Jazz Pharmaceuticals PLC will post $10.89 earnings per share for the current year.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.